Kelun-Biotech’s TROP2 ADC, Sacituzumab tirumotecan (sac-TMT), has received marketing approval from China’s NMPA for second-line or later treatment of advanced or metastatic TNBC.

Merck reveals that the crucial Phase 3 ZENITH study of WINREVAIR™ (sotatercept-csrk) has met its main goal based on interim results.

MaaT Pharma Reports Successful Phase 1b Outcomes, Achieving Main Goal in MaaT033 Assessment for Amyotrophic Lateral Sclerosis (ALS).

The European Commission has authorized BeiGene’s TEVIMBRA for initial therapy of advanced or metastatic esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer.

IGC Pharma Reveals New Phase 2 Interim Findings Showcasing Cognitive Advantages of IGC-AD1 in Alzheimer’s Therapy.

Menarini Group showcases new and updated findings at the 2024 San Antonio Breast Cancer Symposium, emphasizing the importance of ORSERDU® (Elacestrant).

Innovent has announced that SINTBILO® is being included for the first time in China’s National Reimbursement Drug List, along with a new indication for Olverembatinib.

Akeso has announced that Cadonilimab and Ivonescimab are now part of China's national list for reimbursed drugs.

Lecanemab, marketed as LEQEMBI®, has been introduced for Alzheimer's disease treatment in South Korea.

Kelun-Biotech's TROP2 ADC, sacituzumab tirumotecan (sac-TMT), has received marketing authorization from China's NMPA for the treatment of second-line or later advanced metastatic TNBC.

Replimune has been granted Breakthrough Therapy status for RP1 and has filed a Biologics License Application for RP1 with the FDA via the Accelerated Approval Pathway.

OncoVerity Raises Additional Series A Funds to Progress Cusatuzumab for Newly Diagnosed AML.